What are the common and serious adverse effects of ceftriaxone?

Ceftriaxone Side Effects

Ceftriaxone is generally well-tolerated, but clinicians must monitor for common gastrointestinal effects (diarrhea in 2.7% of patients), hematologic abnormalities (eosinophilia in 6%, thrombocytosis in 5.1%), and hepatic enzyme elevations (AST in 3.1%, ALT in 3.3%), while remaining vigilant for serious but rare complications including immune hemolytic anemia, biliary pseudolithiasis, severe neurological toxicity, and life-threatening hypersensitivity reactions. 1

Common Adverse Effects

Gastrointestinal Effects

• Diarrhea/loose stools occur in 2.7% of patients, representing the most frequent adverse effect 1
• Nausea, vomiting, and dysgeusia occur in <1% of cases 1
• Pseudomembranous colitis (C. difficile infection) can develop during or after treatment, with significantly higher rates at 2g daily (0.6%) compared to 1g daily (0.2%) 1, 2
• Pancreatitis, stomatitis, and glossitis have been reported in postmarketing surveillance 1

Hematologic Abnormalities

• Eosinophilia occurs in 6% of patients, thrombocytosis in 5.1%, and leukopenia in 2.1% 1
• Granulocytopenia (0.9%) and coagulopathy (0.4%) are less common 1
• Neutropenia develops in approximately 15-17% of patients regardless of dose (1g vs 2g daily), typically appearing after a median of 12-17 days of therapy 3
• Anemia, hemolytic anemia, lymphopenia, thrombocytopenia, and prolonged prothrombin time occur in <1% 1

Hepatobiliary Effects

• AST elevations occur in 3.1% and ALT elevations in 3.3% of patients 1
• Alkaline phosphatase and bilirubin elevations occur in <1% 1
• Hepatotoxicity incidence reaches 19.7% when ceftriaxone is combined with other hepatically-metabolized medications, substantially higher than the 2.9-13.9% reported in other studies 4
• Hepatic dysfunction including cholestasis has been reported as a cephalosporin class effect 1

Local Reactions

• Injection site pain occurs in 0.6% of patients 1
• Pain, induration, and tenderness at injection sites occur in 1% overall 1
• Phlebitis occurs in <1% after IV administration 1
• IM administration causes warmth, tightness, or induration in 17% with 350 mg/mL concentration and 5% with 250 mg/mL concentration 1

Hypersensitivity Reactions

• Rash occurs in 1.7% of patients 1
• Pruritus, fever, or chills occur in <1% 1
• Urticaria and edema have been reported in postmarketing surveillance 1

Serious Adverse Effects

Immune Hemolytic Anemia

• Immune hemolytic anemia represents 34.9% (30/86) of serious adverse reactions leading to ceftriaxone discontinuation 5
• This complication is particularly dangerous in children with sickle cell disease, where it has caused 11 deaths 5
• Ceftriaxone should be used with extreme caution in patients with sickle cell disease 5
• Isolated cases of agranulocytosis (<500/mm³) occur most commonly after 10 days of treatment with total doses ≥20 grams 1

Biliary Pseudolithiasis

• Biliary pseudolithiasis accounts for 26.7% (23/86) of serious adverse reactions requiring discontinuation 5
• The incidence is remarkably high at 20.7% (one in five pediatric patients), though almost all cases are reversible 5
• Symptomatic precipitation of ceftriaxone calcium salt in the gallbladder occurs particularly at higher doses (≥2 g/day) 1, 6
• Gallbladder sludging can occur and is sometimes associated with liver function abnormalities when using ceftriaxone 7

Neurological Toxicity

• Serious CNS adverse events occurred in 152 cases in French pharmacovigilance data, with 73.7% requiring hospitalization, 10.5% life-threatening, and 7.9% fatal 8
• Patients exhibited convulsions/status epilepticus/myoclonia (49.3%), encephalopathy (29.6%), confused state (22.4%), and hallucinations (10.5%) 8
• Median age of affected patients was 74.5 years with median creatinine clearance of 35 mL/min, indicating elderly patients with renal impairment are at highest risk 8
• Median time to onset is 4 days with median duration of 4.5 days 8
• EEGs performed in 32.9% of cases were abnormal in 74%, confirming ceftriaxone-induced toxicity 8
• Seizures, myoclonus, and non-convulsive status epilepticus have been reported, particularly in patients with renal impairment when dosage was not reduced 1
• If seizures occur, ceftriaxone should be discontinued immediately 1

Severe Cutaneous Reactions

• Acute generalized exanthematous pustulosis (AGEP) and severe cutaneous adverse reactions including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported 1
• Allergic dermatitis and exanthema occur in postmarketing surveillance 1

Renal Effects

• BUN elevations occur in 1.2% of patients 1
• Creatinine elevations and urinary casts occur in <1% 1
• Oliguria, ureteric obstruction, and post-renal acute renal failure have been reported 1
• Renal precipitations can occur, particularly in neonates 1

Neonatal-Specific Risks

• Fatal outcomes with crystalline material in lungs and kidneys have been reported in neonates receiving ceftriaxone with calcium-containing fluids 1
• Ceftriaxone should be administered cautiously to hyperbilirubinemic infants, especially premature ones, due to kernicterus risk 9, 10

Cross-Reactivity and Allergic Considerations

Penicillin Cross-Reactivity

• Historical cross-reactivity estimates of 8-10% between penicillins and cephalosporins were falsely elevated due to pre-1980 cephalosporin contamination with penicillins 11
• Modern data from 417 patients across 12 studies shows actual cross-reactivity of 2.0-4.8%, similar to rates of new drug allergies 11
• Cross-reactivity is primarily based on identical R1 side chains: ceftriaxone shares R1 side chains with ampicillin, amoxicillin, cefotaxime, and cefoxitin 11
• For patients with anaphylaxis history to cephalosporins, negative skin testing should be confirmed before administering parenteral cephalosporins with nonidentical R1 side chains 11

Anaphylaxis

• Anaphylaxis is rare but represents a serious risk 1
• Anaphylactic or anaphylactoid reactions have been reported in postmarketing surveillance 1
• Allergic pneumonitis and bronchospasm can occur 1

Monitoring Recommendations

Laboratory Monitoring

• Full blood count monitoring is indicated for prolonged therapy regardless of dose, given appreciable rates of hematological dyscrasias 3
• Liver function tests should be monitored during prolonged therapy, especially when combined with other hepatically-metabolized medications 4, 3
• Positive direct Coombs' test can occur as a cephalosporin class effect 1
• False-positive urinary glucose tests may occur 1

High-Risk Populations Requiring Enhanced Monitoring

• Elderly patients (median age 74.5 years) with renal impairment (creatinine clearance <35 mL/min) require careful monitoring for neurological toxicity 8
• Patients with sickle cell disease require extreme caution due to hemolytic anemia risk 5
• Pediatric patients receiving prolonged therapy should be monitored for biliary pseudolithiasis 5
• Hyperbilirubinemic and premature neonates require cautious administration 9, 10

Drug Interactions and Complications

IV Line Complications

• Thrombophlebitis can occur with prolonged intravenous use 7
• Infiltration, infection, and nerve compression (particularly in ankle) are potential IV line complications 12

Superinfection

• Genital fungal infection occurs in 0.1% of patients 1
• Moniliasis or vaginitis occur occasionally (<1%) 1
• Superinfection is recognized as a cephalosporin class adverse reaction 1